These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 25697677)

  • 21. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria.
    Falagas ME; Bliziotis IA; Kasiakou SK; Samonis G; Athanassopoulou P; Michalopoulos A
    BMC Infect Dis; 2005 Apr; 5():24. PubMed ID: 15819983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
    McGowan JE
    Am J Med; 2006 Jun; 119(6 Suppl 1):S29-36; discussion S62-70. PubMed ID: 16735148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colistin: still a lifesaver for the 21st century?
    Karaiskos I; Souli M; Galani I; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):59-71. PubMed ID: 27573251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins.
    Paterson DL; Bonomo RA
    Adv Exp Med Biol; 2019; 1145():9-13. PubMed ID: 31364068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
    Moni M; Sudhir AS; Dipu TS; Mohamed Z; Prabhu BP; Edathadathil F; Balachandran S; Singh SK; Prasanna P; Menon VP; Patel T; Patel P; Kaye KS; Menon VP
    Int J Infect Dis; 2020 Nov; 100():497-506. PubMed ID: 32781161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to polymyxins in Gram-negative organisms.
    Jeannot K; Bolard A; Plésiat P
    Int J Antimicrob Agents; 2017 May; 49(5):526-535. PubMed ID: 28163137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multidrug-resistant Gram-negative infections: the use of colistin.
    Michalopoulos AS; Karatza DC
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD; Suresh K
    Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli.
    Domalaon R; De Silva PM; Kumar A; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymyxin B: similarities to and differences from colistin (polymyxin E).
    Kwa A; Kasiakou SK; Tam VH; Falagas ME
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology of infections caused by polymyxin-resistant pathogens.
    Giamarellou H
    Int J Antimicrob Agents; 2016 Dec; 48(6):614-621. PubMed ID: 27865627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
    Zavascki AP
    Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining Colistin with Furanone C-30 Rescues Colistin Resistance of Gram-Negative Bacteria
    Zhang Y; Lin Y; Zhang X; Chen L; Xu C; Liu S; Cao J; Zheng X; Jia H; Chen L; Zhou T
    Microbiol Spectr; 2021 Dec; 9(3):e0123121. PubMed ID: 34730415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
    Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study.
    Yilmaz GR; Dizbay M; Guven T; Pullukcu H; Tasbakan M; Guzel OT; Tekce YT; Ozden M; Turhan O; Guner R; Cag Y; Bozkurt F; Karadag FY; Kartal ED; Gozel G; Bulut C; Erdinc S; Keske S; Acikgoz ZC; Tasyaran MA
    Ann Saudi Med; 2016; 36(3):216-22. PubMed ID: 27236394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn].
    Zhang JP; Yang XS; Chen J; Peng YZ; Huang YS
    Zhonghua Shao Shang Za Zhi; 2009 Oct; 25(5):372-6. PubMed ID: 19951562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.